SCHEMBL13197898

SCHEMBL13197898

COCCOCCCNC(=O)c1nc(NC(=O)Nc2ccc(OC(F)(F)F)cc2)cn1Cc1ccccc1

nearest known ligand 0.44

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
TP53 P04637 1/20 0.44
IGF1R P08069 2/20 0.43
EPHX2 P34913 5/20 0.43
PPARA Q07869 2/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
MCHR1 Q99705 2/20 0.42
LMNA P02545 1/20 0.41
KDM4E B2RXH2 2/20 0.41
TDP1 Q9NUW8 1/20 0.41
ALDH1A1 P00352 2/20 0.41
P2RY1 P47900 1/20 0.40
SERPINE1 P05121 1/20 0.40
FPR2 P25090 1/20 0.40
GAA P10253 1/20 0.40
RECQL P46063 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13197870 0.90 MCHR1 (0.45) EPHX2MCHR1KDM4ETDP1ALDH1A1
SCHEMBL13197879 0.89 EPHX2 (0.45) IGF1REPHX2PPARAMCHR1KDM4E
SCHEMBL13197836 0.89 IGF1R (0.47) TP53IGF1REPHX2PPARASMN1; SMN2
SCHEMBL13197917 0.88 MCHR1 (0.48) TP53IGF1REPHX2PPARASMN1; SMN2
SCHEMBL13197896 0.88 EPHX2 (0.45) TP53IGF1REPHX2PPARASMN1; SMN2
SCHEMBL13197911 0.87 MCHR1 (0.45) EPHX2SMN1; SMN2MCHR1KDM4ETDP1
SCHEMBL13197833 0.87 EPHX2 (0.48) TP53IGF1REPHX2PPARASMN1; SMN2
SCHEMBL13197887 0.87 MCHR1 (0.42) IGF1REPHX2MCHR1KDM4ETDP1
SCHEMBL13197861 0.87 MCHR1 (0.43) EPHX2MCHR1KDM4ETDP1ALDH1A1
SCHEMBL13197905 0.86 MCHR1 (0.42) EPHX2MCHR1KDM4ETDP1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7767704-B2 Antiviral 4-aminocarbonylamino-substituted imidazole compounds AICURIS GMBH & CO. KG (DE) 2010-08-03 US disclosed
US-7767704-B2 Antiviral 4-aminocarbonylamino-substituted imidazole compounds AICURIS GMBH & CO. KG (DE) 2010-08-03 US disclosed
US-20080004275-A1 Antiviral 4-Aminocarbonylamino-Substituted Imidazole Compounds BAYER HEALTHCARE AG (DE) 2008-01-03 US disclosed
US-20080004275-A1 Antiviral 4-Aminocarbonylamino-Substituted Imidazole Compounds BAYER HEALTHCARE AG (DE) 2008-01-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080004275-A1 Antiviral 4-Aminocarbonylamino-Substituted Imidazole Compounds IRF3, EIF2AK2, ZC3HAV1 TP53 935/4885IGF1R 400/4885EPHX2 3922/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.